Organization
Radiomics, Liege, Belgium
3 abstracts
Abstract
Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy, iOnctura SA, Geneva, Switzerland, iOnctura, Geneva, Switzerland, Covance Clinical and Peri-approval Services LTD, Milano, Italy,
Abstract
First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).Org: iOnctura SA, Geneva, Switzerland, iOnctura, Covance Clinical and Peri-approval Services LTD, Milano, Italy, Radiomics, Liege, Belgium,
Abstract
Radiomics to predict checkpoint inhibitor pneumonitis based on chest CT scans in patients with advanced cancer.Org: Radiomics, Liege, Belgium, University Hospital (CHU) of Liège, CHU de Liege, Liege, Belgium, Department of Pneumology, Department of Nuclear Medicine and Oncological Imaging,